Oath Research

Nvelop Therapeutics is a biotechnology company pioneering a modular platform for the in vivo delivery of genetic medicines. The company's core technology, based on engineered virus-like particles (eVLPs), is designed to deliver diverse therapeutic cargoes—including base editors, CRISPR-Cas9, and mRNA—to specific tissues and cell types. By addressing the primary challenge of delivery in genetic medicine, Nvelop aims to expand the reach of curative therapies for patients with previously untreatable diseases. Founded by leaders in gene editing and backed by top-tier venture capital, the company is advancing a pipeline of internal and partnered programs targeting the liver, retina, and central nervous system.